Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 26, 2024

Survival Benefit With Adjuvant Chemotherapy Based on Molecular Residual Disease in Patients With Resected Colorectal Liver Metastases

Annals of Oncology

 

Additional Info

Annals of Oncology
Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: subgroup analysis from CIRCULATE-Japan GALAXY
Ann. Oncol 2024 Sep 16;[EPub Ahead of Print], K Kataoka, K Mori, Y Nakamura, J Watanabe, N Akazawa, K Hirata, M Yokota, K Kato, M Kotaka, K Yamazaki, Y Kagawa, S Mishima, K Ando, M Miyo, H Yukami, G Laliotis, S Sharma, CC Palsuledesai, M Rabinowitz, A Jurdi, MC Liu, A Aleshin, D Kotani, H Bando, H Taniguchi, I Takemasa, T Kato, T Yoshino, E Oki

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading